Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire.

Sena BF, Stern JP, Pandharipande PV, Klemm B, Bulman J, Pedrosa I, Rofsky NM.

AJR Am J Roentgenol. 2010 Aug;195(2):424-8. doi: 10.2214/AJR.09.3803.

PMID:
20651199
2.

Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function.

Chang P, Saddleton E, Laumann AE, Schmitz B, West DP, Belknap SM, Parthasarathy S, Edwards BJ, McKoy JM, Miller FH.

Acad Radiol. 2012 Oct;19(10):1181-5. doi: 10.1016/j.acra.2012.04.016.

3.

Screening for impaired renal function in outpatients before iodinated contrast injection: Comparing the Choyke questionnaire with a rapid point-of-care-test.

Too CW, Ng WY, Tan CC, Mahmood MI, Tay KH.

Eur J Radiol. 2015 Jul;84(7):1227-31. doi: 10.1016/j.ejrad.2015.04.001.

PMID:
25933722
4.

Incidence of nephrogenic systemic fibrosis at two large medical centers.

Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM.

Radiology. 2008 Sep;248(3):807-16. doi: 10.1148/radiol.2483071863.

PMID:
18710976
5.

Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.

Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH.

Radiology. 2011 Jul;260(1):105-11. doi: 10.1148/radiol.11102340.

PMID:
21586680
6.

Serum creatinine measurements: evaluation of a questionnaire according to the ESUR guidelines.

Zähringer C, Potthast S, Tyndall AJ, Bongartz G, Hohmann J.

Acta Radiol. 2015 May;56(5):628-34. doi: 10.1177/0284185114533244.

PMID:
24867223
7.

Can a structured questionnaire identify patients with reduced renal function?

Azzouz M, Rømsing J, Thomsen HS.

Eur Radiol. 2014 Mar;24(3):780-4. doi: 10.1007/s00330-013-3065-x.

PMID:
24275804
8.

Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.

Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'Malley RB, Parsons DJ, Fuller ER 3rd, Semelka RC.

Radiology. 2008 Sep;248(3):799-806. doi: 10.1148/radiol.2483072093.

PMID:
18632533
9.

Fluctuations in eGFR in relation to unenhanced and enhanced MRI and CT outpatients.

Azzouz M, Rømsing J, Thomsen HS.

Eur J Radiol. 2014 Jun;83(6):886-92. doi: 10.1016/j.ejrad.2014.02.014.

PMID:
24656402
10.
11.

Nephrogenic systemic fibrosis: center case review.

Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-Parker S, Martin DR.

J Magn Reson Imaging. 2007 Nov;26(5):1198-203. Review.

PMID:
17969162
12.

Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.

Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.

AJR Am J Roentgenol. 2008 Apr;190(4):1060-8. doi: 10.2214/AJR.07.2822.

PMID:
18356456
13.

Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.

Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC.

J Magn Reson Imaging. 2010 Feb;31(2):440-6. doi: 10.1002/jmri.22024.

14.

Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.

Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA.

Radiology. 2009 Feb;250(2):371-7. doi: 10.1148/radiol.2502080498.

15.

Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.

Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A.

AJR Am J Roentgenol. 2015 Sep;205(3):469-78. doi: 10.2214/AJR.14.14268.

PMID:
26295633
16.

Nephrogenic systemic fibrosis: risk factors and incidence estimation.

Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A.

Radiology. 2007 Apr;243(1):148-57.

PMID:
17267695
17.

Efficacy of patient questionnaire in predicting renal dysfunction in outpatients older than 60 years of age prior to contrast-enhanced computed tomography.

Lui EH, Lau KK, Polkinghorne K, Chang CA, Ardley N.

J Med Imaging Radiat Oncol. 2012 Apr;56(2):168-72. doi: 10.1111/j.1754-9485.2011.02323.x.

PMID:
22498189
18.

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, Rigothier C, Billiouw JM, Campioni P, Ferreiros J, Devos D, Alison D, Glowacki F, Boffa JJ, Marti-Bonmati L.

Eur Radiol. 2013 May;23(5):1250-9. doi: 10.1007/s00330-012-2705-x.

19.

Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.

Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C, Choukroun G, Deray G.

Eur J Radiol. 2010 Feb;73(2):357-9. doi: 10.1016/j.ejrad.2008.11.021.

PMID:
19128909
20.

Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.

Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB.

J Magn Reson Imaging. 2015 May;41(5):1259-67. doi: 10.1002/jmri.24650.

PMID:
24811860
Items per page

Supplemental Content

Support Center